JP Morgan Chase
DYN icon

JP Morgan Chase’s Dyne Therapeutics DYN Stock Holding History

JP Morgan Chase’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$55.6M Sell
3,253,473
-296,436
-8% -$5.11M ﹤0.01% 1331
2025
Q4 		$69.4M Buy
3,549,909
+184,664
+5% +$3.5M ﹤0.01% 1154
2025
Q3 		$42.6M Buy
3,365,245
+278,466
+9% +$3.18M ﹤0.01% 1514
2025
Q2 		$29.4M Buy
3,086,779
+555,466
+22% +$6.12M ﹤0.01% 1669
2025
Q1 		$26.5M Buy
2,531,313
+2,432,926
+2,473% +$34.8M ﹤0.01% 1701
2024
Q4 		$2.32M Sell
98,387
-3,363
-3% -$99.5K ﹤0.01% 4032
2024
Q3 		$3.65M Buy
101,750
+4,236
+4% +$169K ﹤0.01% 3460
2024
Q2 		$3.44M Buy
97,514
+43,144
+79% +$1.25M ﹤0.01% 3332
2024
Q1 		$1.54M Buy
54,370
+12,887
+31% +$291K ﹤0.01% 4044
2023
Q4 		$552K Sell
41,483
-296,691
-88% -$2.9M ﹤0.01% 4727
2023
Q3 		$3.03M Buy
338,174
+302,562
+850% +$3.26M ﹤0.01% 3219
2023
Q2 		$401K Buy
35,612
+8,743
+33% +$103K ﹤0.01% 4627
2023
Q1 		$309K Buy
26,869
+6,425
+31% +$83.4K ﹤0.01% 4791
2022
Q4 		$237K Sell
20,444
-23,332
-53% -$270K ﹤0.01% 4949
2022
Q3 		$557K Buy
43,776
+8,456
+24% +$97K ﹤0.01% 4387
2022
Q2 		$242K Buy
35,320
+7,462
+27% +$51.4K ﹤0.01% 4976
2022
Q1 		$268K Sell
27,858
-9,980
-26% -$85K ﹤0.01% 5031
2021
Q4 		$450K Sell
37,838
-55,845
-60% -$785K ﹤0.01% 4904
2021
Q3 		$1.52M Buy
93,683
+77,835
+491% +$1.38M ﹤0.01% 3986
2021
Q2 		$334K Buy
15,848
+5,679
+56% +$107K ﹤0.01% 4950
2021
Q1 		$158K Buy
10,169
+3,789
+59% +$73.3K ﹤0.01% 5235
2020
Q4 		$134K Buy
+6,380
New +$126K ﹤0.01% 4929

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

JP Morgan Chase's DYN Position: Q1 2026 in Review

JP Morgan Chase reduced its Dyne Therapeutics (DYN) stake by 8.4% in Q1 2026, selling an estimated $5.11M and leaving 3,253,473 shares worth $55.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1331.

JP Morgan Chase first reported a position in DYN in Q4 2020 and has held it in 22 quarters since. The position peaked at $69.4M in Q4 2025. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

  • JP Morgan Chase held 3,253,473 shares of Dyne Therapeutics worth $55.6M as of Q1 2026.
  • JP Morgan Chase sold 296,436 Dyne Therapeutics shares in Q1 2026, an estimated $5.11M.
  • Dyne Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #1331 holding.
  • JP Morgan Chase first reported a position in Dyne Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • JP Morgan Chase's Dyne Therapeutics position peaked at $69.4M in Q4 2025.
  • 227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.